SRNE - Sorrento Therapeutics' Mexico executes second contract for sale of 10M Covistix tests
Sorrento Therapeutics' (NASDAQ:SRNE) Mexican subsidiary has executed a second contract with a large distributor for the sale and distribution of up to 10 million COVISTIX tests for the Mexican market. SRNE previously announced that Sorrento Mexico had signed a contract with a local distributor for up to 5 million COVISTIX tests in Mexico, bringing the total number of tests to 15 million to date. Since its commercial launch in July, the COVISTIX COVID-19 Virus Rapid Antigen Detection Test has been well received for its ease of use and rapid generation of results.
For further details see:
Sorrento Therapeutics' Mexico executes second contract for sale of 10M Covistix tests